Fierce Pharma

FEBRUARY 7, 2024

Despite markedly slower cell therapy growth from the third to the fourth quarter of 2023—and a recent setback for Trodelvy—historically HIV-focused Gilead Sciences is not discouraged amid its | Despite a tame level of fourth-quarter growth, recent advances should drive long-term cell therapy sustainability, Gilead execs said. Overall, the company is pushing to generate 30% of its revenues from oncology by 2030.

229

229

MedCity News

FEBRUARY 7, 2024

Strengthening health IT infrastructure is a critical and necessary step toward abating the opioid crisis and evaluating the impact of how opioid settlement dollars are allocated across communities.

Pharma 127

Pharma 127

Fierce Pharma

FEBRUARY 7, 2024

Even with Leqembi now sporting a full FDA approval and benefiting from the simpler Medicare coverage that distinction brings, Eisai and Biogen’s latest Alzheimer’s disease med appears to be moving | While Japan’s Eisai had set the goal to reach 10,000 patients with Leqembi by the end of its 2024 fiscal year, which wraps up in March, only 2,000 patients in the U.S. were receiving the amyloid-busting antibody as of Jan. 26, Eisai explained in a third-quarter earnings presentation.

FDA 220

FDA Patients 220

MedCity News

FEBRUARY 7, 2024

Establishing site-neutral payments for outpatient services is a hot issue in Capitol Hill right now. Advocates say that such policy would lower healthcare costs, saving both patients and taxpayers money. Opponents say that it would put hospitals’ financial security at risk and jeopardize access to care.

Healthcare 111

Healthcare Healthcare Patients 111

Advertiser: ZoomInfo

Modern go-to-market teams know it takes more than one email to break through the noise. Multiple touchpoints means more ways to get your pitch right — and, potentially, more ways to be wrong. The good news? Once you know how to write compelling, one-off emails to entice prospective customers, you can easily do the same across a short sequence of emails.

Fierce Pharma

FEBRUARY 7, 2024

As part of the acquisition of manufacturing giant Catalent, Novo Nordisk will fork over $11 billion for three of the CDMO’s plants. | While Catalent’s Bloomington, Indiana, site is no stranger to FDA reprimands, its latest write-up is notable given that the site forms part of the $16.5 billion deal Novo Holdings struck to acquire Catalent earlier this week.

Manufacturing 218

Manufacturing FDA 218

PharmaTimes

FEBRUARY 7, 2024

The HTA reported that Brainomix 360 improved access to treatment for stroke patients

Patients 107

Patients 107

European Pharmaceutical Review

FEBRUARY 7, 2024

AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland, which will focus initially on T-cell therapies for oncology indications. The site will launch the company’ s cell therapy platforms in the US for critical cancer trials and future commercial supply. The site may widen its focus to support other disease areas, according to AstraZeneca.

Manufacturing 103

Manufacturing Medicine Networking Patients 103

Fierce Pharma

FEBRUARY 7, 2024

Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer. | Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer. Meanwhile, the Indianapolis pharma has another phase 3 prostate cancer program in the works.

Pharma 200

Pharma 200

Pharmaceutical Technology

FEBRUARY 7, 2024

Gilead Sciences has announced a 22.9% increase in net income of $5.61bn for FY23 as against $4.56bn in FY22.

98

98

Fierce Pharma

FEBRUARY 7, 2024

After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepez | After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepezza—an instant blockbuster that saw a perplexing slide in just its third full year on the market.

Sales 197

Sales Marketing 197

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

pharmaphorum

FEBRUARY 7, 2024

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into targeted cancer therapies. Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright, including multiple preclinical-stage drug candidates, and will take responsibility for ushering the most promising compounds through clinical trials and onto the market.

Pharma 97

Pharma Pharmaceutical Marketing 97

Fierce Pharma

FEBRUARY 7, 2024

With an upfront payment of $100 million, Kyowa Kirin has bought into a partnership with BridgeBio to develop and commercialize infigratinib in Japan.

173

173

European Pharmaceutical Review

FEBRUARY 7, 2024

A paper published in Biotechnology Progress has explored real-time deviation management for integrated continuous bioprocesses and highlighted the role of automation. The discussion was based on a case study produced by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Specifically, the case study discussed a control strategy in the context of integrated continuous bioprocesses ( ICB ) for monoclonal antibodies (mAbs).

Management 97

Management Leads Manufacturing Pharmaceutical 97

Pharmaceutical Technology

FEBRUARY 7, 2024

AstraZeneca is investing $300m in a facility in Rockville, US - a significant step in launching its cell therapy platforms in the country.

97

97

Advertiser: ZoomInfo

Account-based marketing (ABM) is a key strategy for driving sustainable growth. Today, many B2B companies use ABM teams or technologies to make sales. But getting a program off the ground successfully doesn’t have to be a daunting task. Watch this webinar with Rachael Foster, Director of Account-Based Experience at ZoomInfo, and Dan Dolph, Manager of Account-Based Experience at ZoomInfo.

MedCity News

FEBRUARY 7, 2024

Gilead Sciences said an independent review of interim Phase 3 data found the immunotherapy, magrolimab, led to a higher risk of death. Though Gilead is discontinuing further development of the drug in blood cancers, a review is ongoing in solid tumors.

Safety 95

Safety Leads FDA Biopharma 95

PharmaTimes

FEBRUARY 7, 2024

The new products are in the areas of gastrointestinal and respiratory medicines

Medicine 92

Medicine 92

pharmaphorum

FEBRUARY 7, 2024

Jewish people in England are being asked to have gene testing for BRCA mutations that elevate their risk of breast cancer

91

91

MedCity News

FEBRUARY 7, 2024

Providing patients with comprehensive patient resource sheets on clinical trials can alleviate worry, support dialog with family members and clinical care providers and empower informed decision-making.

Patients 88

Patients Healthcare Healthcare Education 88

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

FEBRUARY 7, 2024

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there but was withdrawn from sale after it failed a confirmatory trial.

Sales 88

Sales Marketing 88

MedCity News

FEBRUARY 7, 2024

Amazon has eliminated “a few hundred” jobs across Amazon Pharmacy and One Medical, the company confirmed to MedCity News Wednesday. While some may believe this could lead to Amazon leaving healthcare, one industry expert said that would be an “overly simplistic” takeaway.

Healthcare 86

Healthcare Healthcare Medical Leads 86

pharmaphorum

FEBRUARY 7, 2024

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.

Manufacturing 76

Manufacturing Sales 76

Pharmaceutical Technology

FEBRUARY 7, 2024

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

75

75

Advertiser: ZoomInfo

How will generative AI transform sales? It’s a question that promises to drive billions of dollars in revenue opportunities over the next five to 10 years. And if you’re not leveraging AI solutions in your go-to-market motions, you’re already behind. In this eBook, we’ll cover: How today’s top sales leaders are incorporating AI into their go-to-market motions.

PharmaVoice

FEBRUARY 7, 2024

Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation.

Pharma 64

Pharma 64

Pharmaceutical Technology

FEBRUARY 7, 2024

Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.

Food 75

Food 75

pharmaphorum

FEBRUARY 7, 2024

Life sciences communications agency Real Chemistry has more than doubled its medical team through the acquisition of Avant Healthcare. The takeover – which was completed earlier this month for an undisclosed sum – will bolster Real Chemistry’s medical education, medical affairs, and healthcare provider (HCP) communications capabilities, said the company in a statement.

Healthcare Provider 59

Healthcare Provider Education Medical Healthcare 59

Pharmaceutical Technology

FEBRUARY 7, 2024

(Sacubitril + valsartan) is under clinical development by Novartis and currently in Phase II for Hypertrophic Cardiomyopathy.

74

74

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmacy Times

FEBRUARY 7, 2024

The 23-valent pneumococcal polysaccharide vaccine was most likely associated with a higher risk of immunological events for those who were immunocompromised, but the events were low.

Safety 55

Safety 55

Pharmaceutical Technology

FEBRUARY 7, 2024

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).

Pharma 71

Pharma 71

Pharmacy Times

FEBRUARY 7, 2024

Investigators also found that the mortality rates for cardiovascular disease from 2020 to 2022 reversed the improvements of reduced mortalities in the preceding decades.

55

55

Pharmaceutical Technology

FEBRUARY 7, 2024

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Carcinoma.

71

71

Advertiser: ZoomInfo

As marketing becomes more tech-driven, the role of marketing operations (MOps) is getting more complex. Today, the discipline is increasingly interwoven with other vital go-to-market motions — including sales and customer support — and is responsible for all business elements associated with marketing, including the tech stack. In this eBook, we’ll show you how marketing operations can create efficiencies in your tech stack, reporting, and budget that will not just improve internal processes, bu

Marketing